COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium

Hana Morrissey, Patrick Ball, Anandadeep Mandal, Alan Nevill, Shankara Paneesha, Supratik Basu, Farheen Karim, Mohammed Imran, Neil Phillips, Jahanzeb Khawaja, Jackie Stone, Duncan Murray, Katie Randall, Vidhya Murthy, Bhuvan Kishore, Manos Nikolousis, Guy Pratt, Jeff Neilson, Nick Pemberton, Farooq Wandroo

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Since COVID‐19 first appeared it has been clear that whilst many patients experience relatively minor symptoms, some develop a more serious disease. Studies have suggested that oncology patients, including those with haematological malignancies, have a greater risk of severe COVID‐19 disease with increased morbidity and mortality. This retrospective study, conducted by clinicians and researchers from nine West Midlands hospitals, included all adult patients with both an underlying haematological disorder and confirmed COVID‐19, diagnosed between 1st March and 31st May 2020. Demographic, clinical, laboratory, radiological and outcome data were collected using a standardised form. COVID‐19 was diagnosed by reverse transcription‐polymerase chain reaction. An ethical clearance waiver for the audit was received from the nine hospitals involved.
Original languageEnglish
Pages (from-to)e11-e14
Number of pages4
JournalBritish Journal of Haematology
DOIs
Publication statusPublished - 05 Nov 2021

Fingerprint

Dive into the research topics of 'COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium'. Together they form a unique fingerprint.

Cite this